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1. Introduction
HTLV-1 (human T-cell leukemia virus type 1) is a human retrovirus and the causative agent
of ATL (adult T-cell leukemia), which is an aggressive and fatal T cell malignancy character‐
ized by dysregulated proliferation of CD4-positive T cells [1-3]. HTLV-1 causes ATL in 3-5%
of infected individuals after a long latent period of 40-60 years [4]. The prognosis of patients
with aggressive ATL remains poor with a median survival time of less than 1 year despite
advances in both chemotherapy and supportive care [5, 6]. Infiltration of leukemic cells into
various organs, such as lymph nodes, liver, spleen, lung, skin and intestinal tract, is a fre‐
quent manifestation of ATL. This type of cell infiltration often poses serious clinical prob‐
lems for ATL patients, affecting the disease profile and prognosis. Because tumor cell
survival and growth are maintained by nutrients, especially glucose and oxygen supplied
by blood vessels, angiogenesis is considered to be essential for tumor malignancy [7].
Currently, the molecular mechanism of malignant transformation by HTLV-1 remains unde‐
fined. However, Tax, the 40-kDa transactivator protein encoded by HTLV-1, plays a crucial
role in T cell transformation and leukemogenesis. Tax triggers viral transcription as well as
induction of cellular genes involved in cell proliferation and anti-apoptotic signaling. In ad‐
dition to activation of transcription, Tax transforms the infected cells by some mechanisms
due to protein-protein interaction between Tax and other proteins [8, 9]. Moreover, one key
feature of ATL is aneuploidy and chromosomal instability. Tax also contributes transforma‐
tion of the cells by inducing aneuploidy and inactivating chromosomal instability check‐
point [10]. Indeed, it immortalizes primary human T cells derived from peripheral blood or
cord blood [11, 12] and induces tumors and leukemia in transgenic mice [13, 14].
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NF-κB (nuclear factor κB) is a major survival signaling pathway activated by HTLV-1. This
pathway is constitutively active in HTLV-1-transformed T-cells and primary ATL cells [15,
16].Tax can activate NF-κB pathway by associating with various signaling molecules in this
pathway. For example, Tax binds IKKγ (also known as NEMO) and triggers the phosphoryla‐
tion of IKKα and IKKβ, which form a complex with IKKγ [15]. Subsequently the IKK complex
phosphorylates IκBα, leading to its proteasome-mediated degradation, which frees IκBα-se‐
questered cytoplasmic NF-κB to migrate into the nucleus where it activates the transcription of
NF-κB-responsive genes [15]. Tax can also stimulate an alternative NF-κB pathway through
the IKKα-dependent processing of the NF-κB p100 precursor protein to its active p52 form [17].
The NF-κB signaling pathways are activated in ATL cells that do not express Tax, although the
mechanism of activation remains unknown [16]. One of the potential mechanisms by which
ATL cells could develop resistance to apoptosis is through the activation of NF-κB. From this
point of view, NF-κB has become an attractive target for therapeutic intervention.
AMPK (AMP-activated protein kinases) are a class of serine/threonine kinases that are activat‐
ed by increased intracellular concentrations of AMP. ARK5 is a fifth member of the AMPK cat‐
alytic subunit family [18-20], and involved in tumor invasion and metastasis [21], and also
known to induce cell survival during nutrient starvation or death receptor activation [22, 23].
ARK5 promoter contains two putative MARE (Maf-recognition element) sequences [24]. The
maf proto-oncogene is identified within the genome of the avian musculoaponeurotic fibrosar‐
coma virus, AS42 [25]. The products of the Maf family share a conserved bZip motif that medi‐
ates dimer formation and DNA binding to the MARE [26]. Transcription of ARK5 gene is
regulated by the large Maf-family proteins including c-Maf and MafB. ARK5 is induced when a
c-Maf or MafB expression vector is introduced into non-ARK5-expressing colon cancer cells
[24]. Deregulated expression of ARK5 is also associated with Maf-transforming activity in hu‐
man angioimmunoblastic T-cell lymphoma and in Maf-driven T-cell lymphoma in transgenic
mice [27]. In multiple myeloma cells, over expression of ARK5 correlates with the expression of
c-Maf and MafB and exhibits increased invasiveness [24]. ARK5 mRNA expression in colon
cancer is stage-associated and liver metastatic foci of colon cancer express very high levels of
ARK5 mRNA [28, 29]. In this study, we focused on ARK5 and analyzed its expression and role
on the growth of HTLV-1-infected T-cells.
2. Materials and methods
2.1. Reagents
Bay 11-7082 and LY294002 were purchased from Calbiochem. D-(+)-glucose was purchased
from Nakalaitesque.
2.2. Cell lines
The HTLV-1-uninfected T-cell leukemia cell lines MOLT-4 and CCRF-CEM, the HTLV-1-in‐
fected T-cell lines MT-2 [30], MT-4 [31],C5/MJ [32], SLB-1 [33], HUT-102 [1], MT-1 [34] and
TL-OmI [35]were maintained in RPMI 1640 medium supplemented with 10% heat-inactivat‐
ed fetal bovine serum, 50 units/ml penicillin, and 50 μg/ml streptomycin (Sigma-Aldrich) at
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37˚C in 5% CO2. MT-2, MT-4, C5/MJ and SLB-1 are HTLV-1-transformed T-cell lines which
were established by an in vitro coculture protocol. MT-1 and TL-OmI are leukemic T-cell
lines derived from patients with ATL. HUT-102 was established from a patient with ATL,
but its clonal origin is unclear. TY8-3 is an IL-2-dependent cell line established from a thy‐
moma specimen of a myasthenia gravis patient. TY8-3/MT-2 cells were established from
TY8-3 cells by coculture with mitomycin C-treated HTLV-1-infected MT-2 cells in the pres‐
ence of IL-2 [36]. JPX-9 and JPX/M (kindly provided by Dr. M. Nakamura, Tokyo Medical
and Dental University, Tokyo, Japan) are subclones of Jurkat cells that express Tax wild type
and Tax mutant protein defective in its some abilities including activation of NF-κB, respec‐
tively, under the control of the metallothionein promoter [37]. Expression of Tax was in‐
duced by addition of CdCl2 to a final concentration of 20 μM.
2.3. RT (reverse transcriptase)-PCR
Total cellular RNA was extracted from cells using Trizol reagent as described by the supplier
(Invitrogen). First-strand cDNA was synthesized in a 10-μl reaction volume using RNA-PCR
kit (TAKARA BIO) with random primers. Thereafter, cDNA was amplified for ARK5 and c-
Maf. The oligonucleotide primers used were as follows: for ARK5; sense, 5’- GAGTCCACTC‐
TATGCATC-3’  and  antisense,  5’-  ATGTCCTCAATAGTGGCC-3’;  for  c-Maf;  sense,  5’-
TGCACTTCGACGACCGCTTCT C-3’ and antisense, 5’- CGCTGCTCGAGCCGTTTTCTC-3’.
Product sizes were 256-bp for ARK5 and 327-bp for c-Maf. The amplification programs were
follows: denaturing at 94˚C for 2 min, an annealing step at 55˚C for 30 s and an extension step
at 72˚C for 30 s. Amplification cycles were 35 cycles for ARK5 and c-Maf, 25 cycles for β-actin.
The PCR products were fractionated on 2% agarose gels and visualized by ethidium bromide
staining.
2.4. Real-time RT-PCR
Total RNA was extracted from cells with Trizol reagent. Total RNA was reverse transcribed
to obtain single-strand cDNA with High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). PCR was carried out in a total volume of 25 μl of reaction mixture containing 1
μl of diluted cDNA, 12.5 μl of Brilliant SYBR® Green QPCR Master Mix (Stratagene), and
100 nM of each primer with a Mx3000P® Real-Time PCR System (Stratagene). For precise
quantitative determination of the transcripts, we assessed the expression levels of GAPDH
as an internal control. PCR conditions were set according to the instructions supplied by the
manufacturer. The real-time PCR assay of each sample was conducted in triplicate, and the
mean value was used as the mRNA level. The PCR primer pairs used in this study for ARK5
and c-Maf are listed above and those for Tax and GAPDH were as follow: for Tax; sense, 5’-
CCCACTTCCCAGGGTTTGGACAGA-3’ and antisense, 5’- CTGTAGAGCTGAGCCGA‐
TAACGCG-3’; for GAPDH; sense, 5’-GAGTCAACGGATTTGGTCGT-3’ and antisense, 5’-
GACAAGCTTCCCGTTCTCAG-3’.
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2.5. Western blot analysis
Western blot analysis was performed as described previously [38]. In brief, cells were lysed
in sodium dodecyl sulfate (SDS) sample buffer containing 62.5 mM Tris-HCl (pH 6.8), 2%
(wt/vol) SDS, 10% glycerol, 6% 2-mercaptoethanol and 0.01% bromophenol blue. The lysates
were resolved by electrophoresis on polyacrylamide gels and then electroblotted onto poly‐
vinylidene difluoride membranes (Millipore). The membranes were incubated overnight
with the appropriate primary antibody, as indicated, at 4°C. After washing, the blots were
exposed to the appropriate secondary antibody conjugated with horseradish peroxidase for
1 h at room temperature. The reaction products were visualized using enhanced chemilumi‐
nescence reagent (GE Healthcare) according to the instructions provided by the manufactur‐
er. We used primary antibodies against Tax (Lt-4) [39], phosphorylated IκBα (Ser32/36),
phosphorylated AKT(Ser473), AKT, NF-κB (p65) (Cell Signaling Technology), IκBα, (Santa
Cruz Biotechnology) and actin (Lab Vision). Horseradish-peroxidase-conjugated secondary
antibodies were purchased from GE Healthcare.
2.6. Plasmids
The reporter assay construct for ARK5 promoter was described previously [24]. In brief,
based on the results of a Genomic BLAST Search, primers with the NheI (upstream primer)
or XhoI (downstream primer) site were synthesized, and PCR was then performed with the
primers for genomic DNA extracted from PANC-1 cells. The PCR fragment digested with
NheI and XhoI was ligated into pGL2-basic.A series of expression vectors for Tax (Tax WT)
and mutants thereof (Tax M22 and Tax 703) were described previously [40, 41]. IκBα ΔN
and IκBβ ΔN are deletion mutants of IκBα and IκBβ lacking the N-terminal 36 amino acids
and 23 amino acids, respectively. IKKβ K44A and NEMOΔC are the dominant negative mu‐
tants of IKKβ and NEMO, respectively [42, 43]. The expression vector for mouse c-Maf was
described previously [44]. NF-κB (p65) expression plasmid was described previously [45].
2.7. Transfection and luciferase assay
Transfections were performed in CCRF-CEM cells by electroporation with Microporator
MP-100® (Digital Bio Technology) according to the instructions supplied by the manufactur‐
er for optimization and use. In all cases, the reference plasmid phRL-TK, which contains the
Renilla luciferase gene under the control of the Herpes simplex virus thymidine kinase pro‐
moter, was cotransfected to correct for transfection efficiency. Then cells were collected by
centrifugation and lysed in reporter lysis buffer (Promega). Luciferase assays were per‐
formed by using the Dual-Luciferase Reporter System (Promega), in which relative lucifer‐
ase activities were calculated by normalizing transfection efficiency according to the Renilla
luciferase activities.
2.8. siRNA (small interfering RNA)
To knockdown ARK5 and c-Maf expression, predesigned double-stranded siRNAs (siGE‐
NOME SMART pool Human ARK5 and Human MAF;Dharmacon) were used. The siCON‐
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TROL non-targeting siRNA pool (Dharmacon) was used as a negative control. siRNAs were
transfected into MT-2 cells by electroporation with MicroporatorMP-100®.
2.9. EMSA (electrophoretic mobility-shift assay)
Nuclear extracts were prepared from cells and DNA-binding activity was analyzed by EM‐
SA, as described previously [16]. Briefly, 5 μg of nuclear extracts were pre-incubated in a
binding buffer containing 1 μg poly-deoxy-inosinic-deoxy-cytidylic acid (Amersham Bio‐
sciences), followed by addition of [α-32P]-labeled oligonucleotide probe. These mixtures
were incubated for 15 min at room temperature. The DNA-protein complexes were separat‐
ed on 4% polyacrylamide gels and visualized by autoradiography. The probes or competi‐
tors used were prepared by annealing the following sense and antisense synthetic
oligonucleotides: NF-κB binding sites ARK5 κB A and ARK5 κB B derived from the ARK5
gene promoter 5’- gatcCTCTTGGGGTTCTCCTGGAC-3’ and 5’-gatcAGGTGGGG‐
GAAGCCCTGGCT-3’, respectively. Mutants ARK5 κB A and ARK5 κB B are 5’-
gatcCTCTTGGCCACGAGCTGGAC-3’and 5’-gatcAGGTGGGCCTCCAGCTGGCT-3’,
respectively. To identify NF-κB proteins in the DNA-protein complex identified by EMSA,
we used antibodies specific for various NF-κB family proteins, including p50, p65, c-Rel,
RelB and p52 (Santa Cruz Biotechnology), to elicit a supershift DNA-protein complex forma‐
tion. These antibodies were incubated with the nuclear extracts for 45 min at room tempera‐
ture before incubation with radiolabeled probes.
2.10. Cell proliferation assay
The cells transfected with siRNA were incubated for 12 h, then seeded into 24-well plates at
1×105 viable cells per well, and incubated in glucose-containing or non-containing medium
for the indicated time periods. The number of viable cells was determined every 24 h by
counting trypan blue-excluding cells in a hemocytometer.
2.11. Statistical analysis
Data were expressed as mean ± SD. Differences between groups were analyzed by the un‐
paired Student’s t-test. A p value less than 0.05 denoted the presence of a statistically signifi‐
cant difference.
3. Results
3.1. ARK5 and c-Maf are highly expressed in HTLV-1-infected T-cell lines
Expression of ARK5 and c-Maf mRNA was examined in 6 HTLV-1-infected (MT-2, MT-4,
C5/MJ, SLB-1, HUT-102, MT-1 and TL-OmI) and 2 HTLV-1-uninfected (MOLT-4 and CCRF-
CEM) T-cell lines. ARK5 mRNAs were detectable in all HTLV-1-infected T-cell lines, but not
in uninfected T-cell lines (Figure 1A, left panel). c-Maf expression was relatively higher in
HTLV-1-infected T-cell lines than in HTLV-1-uninfected T-cell lines (Figure 1A, right panel).
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The high expression of MafB was detected only in HTLV-1-infected MT-2 cells, but no dif‐
ferences in expression were noted between other infected and uninfected T-cell lines (results
not shown). Although Tax protein was not detectable in ATL-derived T-cell lines (Figure
1C), Tax mRNA was expressed in all HTLV-1-infected T-cell lines by real time RT-PCR,
which is more sensitive method than Western blot (Figure 1B). These results suggest a close
association between HTLV-1 infection and induction of ARK5 and c-Maf mRNA expression.
Figure 1. Overexpression of ARK5 and c-Maf in HTLV-1-infected T-cell lines. The expressions of ARK5, c-Maf (A) and
Tax (B) mRNAs were analyzed in HTLV-1-infected (HTLV-1; +) and uninfected (HTLV-1; -) T-cell lines by real time RT-
PCR. Results are shown as fold change of mRNA expression relative to that of TL-OmI (ARK5 and Tax) or CCRF-CEM (c-
Maf). Real time RT-PCR data were obtained using the ΔΔCt method, with normalization to the reference GAPDH
mRNA. Data are mean ± SD of triplicate experiments. Numbers on MT-2, MT-4, and SLB-1 represent the actual values.
(C) Western blotting was used to determine the expression of Tax protein. Actin was a loading control.
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3.2. HTLV-1 Tax induces ARK5 and c-Maf expression in T cells
To examine the direct association between ARK5 or c-Maf mRNAs induction and HTLV-1
infection, we used HTLV-1-infected TY8-3/MT-2 cells, which were established from TY8-3
cells by cocultivation with HTLV-1-infected MT-2 cells [36]. Although MafB expression level
was slightly increased in TY8-3/MT-2 cells (results not shown), the expression of ARK5 and
c-Maf mRNAs was clearly higher in TY8-3/MT-2 cells than parental TY8-3 cells (Figure 2A).
Because Tax induces various cellular genes, we next examined whether this includes the ex‐
pression of ARK5 and c-Maf mRNAs in T cells. We used JPX-9 cells, which stably carry Tax
expression plasmid, in which Tax expression is induced by the addition of CdCl2 [37]. The
expression of ARK5, c-Maf, and Tax mRNAs was analyzed by real time RT-PCR (Figure 2B).
The addition of CdCl2 to the culture medium of JPX-9 cells induced the expression of Tax
within 2 h, which persisted until 72 h after treatment. A concomitant increase of ARK5
mRNA within 10 h of treatment with CdCl2 was observed in JPX-9 cells. Rapid expression of
c-Maf mRNA was also observed within 2 h, and peaked after 10 h of treatment with CdCl2.
The induction of ARK5 or c-Maf could not be attributed to CdCl2 treatment, since ARK5 or
c-Maf expression was not induced in JPX/M cells, which express Tax mutant protein, after
treatment with CdCl2 (results not shown). These results indicate that Tax can increase the
expression of ARK5 and c-Maf in T cells.
Figure 2. HTLV-1 Tax induces the expression of ARK5 and c-Maf mRNAs. (A) Infection of HTLV-1 induced ARK5 and c-
Maf mRNA expression. The expression levels of ARK5 and c-Maf mRNAs in TY8-3 cells and HTLV-1-infected TY8-3 cells
established by coculture with MT-2 cells were analyzed by RT-PCR. MT-2 was a positive control. Representative results
of three experiments with similar results. (B) Tax expression was induced by adding CdCl2 (20 μM) in JPX-9 cells. Cells
were harvested at the indicated time points. ARK5, c-Maf, and Tax mRNA expression levels were analyzed by real time
RT-PCR. Results are shown as fold change of mRNA expression relative to that at 0 h (c-Maf), 2 h (Tax), and 10 h
(ARK5). Real time RT-PCR data were obtained using the ΔΔCt method, with normalization to the reference GAPDH
mRNA. Data are mean ± SD of triplicate experiments.
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3.3. c-Maf does not alter ARK5 expression in T cells
ARK5 gene promoter contains two putative MARE sequences [24]. c-Maf and MafB induce
the gene transcription through interaction with MARE on the promoter region of target gene
[26, 46]. ARK5 is induced when a c-Maf expression vector is introduced into non-ARK5-ex‐
pressing colon cancer cells [24]. Our findings of a strong correlation between ARK5 and c-
Maf expression in HTLV-1-infected T-cell lines and Tax inducible JPX-9 cells suggest that
ARK5 could be regulated by c-Maf which is induced by Tax in these cells. However, transi‐
ent transfection of c-Maf expression plasmid into ARK5-negative CCRF-CEM cells did not
induce ARK5 mRNA expression (Figure 3A). Furthermore, c-Maf did not induce transcrip‐
tional activation of ARK5 gene promoter reporter plasmid (Figure 3B) and knockdown of c-
Maf expression in MT-2 cells by siRNA did not affect the expression level of ARK5 mRNA
(Figure 3C). These results suggest that c-Maf does not contribute to induction of ARK5 tran‐
scription in T lymphocytes.
3.4. Tax activates ARK5 transcriptional activity through NF-κB pathway
Next, we investigated whether Tax could directly enhance the activity of ARK5 promoter.
CCRF-CEM cells were transiently transfected with a reporter gene construct containing the
ARK5 promoter together with Tax. Tax enhanced the transcriptional activity of this reporter
(Figure 4A). We analyzed the nucleotide database and found two putative NF-κB sites on the
promoter of ARK5 gene. Tax stimulates transcription through distinct transcription factors,
such as NF-κB and CREB (cyclic AMP response element-binding protein). Therefore, we tested
two mutant forms of Tax; Tax M22 and Tax 703 [40, 41], to investigate whether Tax-mediated
activation of NF-κB signaling pathway was required for induction of the ARK5 promoter acti‐
vation in T cells. Tax M22 activates CREB but does not affect NF-κB, while Tax 703 activates NF-
κB but does not affect CREB [41]. In the present experiments, Tax 703, but not Tax M22,
activated the ARK5 promoter reporter (Figure 4A). Blocking NF-κB signaling pathway using
various dominant negative forms of these signaling molecules reduced Tax-induced activation
of ARK5 promoter (Figure 4B). The nuclear extracts from HTLV-1-infected T-cell lines showed
high NF-κB DNA-binding activity by EMSA using both NF-κB binding sites; denoted as ARK5
κB A and B sites, in the ARK5 promoter as probes. In contrast, no significant DNA-binding ac‐
tivity was detected in extracts of HTLV-1-uninfected T-cell lines (Figure 4C). Competition and
supershift assays showed that the observed DNA-protein complexes were specific for either
ARK5 κB A or B site and included NF-κB components; p50, p65 or c-Rel proteins (Figure 4D).
Transient transfection of NF-κB p65 expression plasmid in CCRF-CEM cells showed that over‐
expression of NF-κB p65 induced promoter activity of ARK5 gene (Figure 4E) and expression of
ARK5 mRNA (Figure 4F). These results suggest that NF-κB activation directly contributes to
induction of the ARK5 gene expression by Tax.
3.5. NF-κB inhibitor suppresses ARK5 expression in an HTLV-1-infected T-cell line
NF-κB is constitutively activated not only in HTLV-1 transformed T-cell lines but also in
ATL-derived T-cell lines and primary ATL cells [16]. We analyzed the effects of an NF-κB
inhibitor Bay11-7082, an inhibitor of phosphorylation of IκBα, on the expression of ARK5 in
an HTLV-1-infected T-cell line. The expression of ARK5 mRNA in MT-2 cells was reduced
T-Cell Leukemia - Characteristics, Treatment and Prevention8
by treatment with Bay11-7082 (Figure 5A, left panels). Inhibition of phosphorylation of IκBα
and stabilization of IκBα protein were confirmed by Western blotting (Figure 5A, upper
right panels). LY249002, a PI3K (phosphatidyl inositol3-kinase)/AKT inhibitor, did not affect
the expression of ARK5 (Figure 5A, left panels). Using Western blotting, we also confirmed
inhibition of phosphorylation of AKT by LY294002 (Figure 5A, lower right panels). Inhibi‐
tion of NF-κB DNA-binding activity by Bay11-7082 was also detected by EMSA using oligo‐
nucleotide probes of ARK5 κB A and B sites (Figure 5B). These results support out findings
in Figure 4 that indicate the contribution of NF-κB signaling to induction of ARK5 gene ex‐
pression in HTLV-1-infected T-cells.
Figure 3. Maf does not affect ARK5 expression in T-cells. (A) c-Maf does not induce ARK5 mRNA expression in HTLV-1-
negative T cells. ARK5 mRNA expression in CCRF-CEM cells 48 h after transfection with increasing amounts of c-Maf
expression plasmids (0, 0.1, 0.5 and 1 μg) were analyzed by real time RT-PCR (left panel). Transfected c-Maf mRNA
expression was confirmed by real time RT-PCR (right panel). (B) c-Maf does not induce ARK5 promoter activity. CCRF-
CEM cells were transfected with increasing amount of c-Maf expression plasmid together with ARK5promoter report‐
er plasmid. Cells were harvested 48 h after transfection and luciferase activity was analyzed. Data are mean ± SD of
triplicate experiments. (C) Knockdown of c-Maf did not reduce ARK5 expression in HTLV-1-infected T cells. MT-2 cells
were transfected with either ARK5, c-Maf or control siRNA (100nM). The expressions of c-Maf and ARK5 mRNAs were
analyzed by RT-PCR. β-actin was a loading control. Representative results of triplicate experiments with similar results.
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Figure 4. Tax activates ARK5 promoter activity via NF-κB signaling pathway. (A) CCRF-CEM cells were transfected with
increasing amounts (0, 0.1, 0.5or 1 μg) of Tax wild type (WT) or mutant (M22 and 703: deficient in NF-κB and CREB
signaling activation, respectively) expression plasmids together with ARK5 gene promoter reporter plasmid. Cells were
collected 48 hr after transfection and luciferase activity was analyzed. Data are mean ± SD of triplicate experiments.
The activity was expressed relative to that of cells transfected with reporter plasmid alone, which was defined as 1. (B)
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CCRF-CEM cells were transfected with various dominant negative forms of NF-κB signaling proteins (0.1 μg) and Tax
expression plasmid (1 μg) together with ARK5 reporter plasmid. Cells were harvested 48 h after transfection and luci‐
ferase activity was analyzed. Data are mean ± SD of triplicate experiments. The activity was expressed relative to that
of cells transfected with reporter plasmid alone, which was defined as 1. (C) DNA-binding of NF-κB proteins to ARK5
gene promoter in HTLV-1-infected T-cell lines. DNA-binding of NF-κB proteins to ARK5 promoter was analyzed by EM‐
SA using the ARK5 κB A (top) andARK5 κB B (bottom) oligonucleotide probes containing the NF-κB-binding sites from
ARK5 gene. (D) NF-κB subunit specificity was determined using nuclear extracts from MT-2 cells and antibodies to NF-
κB components p50, p65, c-Rel, RelB and p52, resulting in super shift. Cold competition using 1, 10 or 100-fold excess
of unlabeled probes (wild type probe; WT) or 100-fold excess mutated probe(mutant probe; Mut) demonstrated the
specificity of the protein-DNA-binding complex. Arrows indicate specific complexes of NF-κB with ARK5 κB A or ARK5
κB B oligonucleotides, and arrowheads indicate super shift of the bands by antibodies against p50, p65, or c-Rel. (E)
NF-κB p65 activates ARK5 promoter activity. CCRF-CEM cells were transfected with increasing amounts (0, 0.1, 0.5 or 1
μg) of NF-κB p65 expression plasmid together with ARK5 promoter reporter plasmid. Cells were harvested 48 h after
transfection and luciferase activity was analyzed. Data are mean ± SD of triplicate experiments. The activity was ex‐
pressed relative to that of cells transfected with reporter plasmid alone, which was defined as 1. The expression of NF-
κB p65 was confirmed by Western blotting (lower panel). (F) The expression of ARK5 mRNA induced by NF-κB p65 was
analyzed by real time RT-PCR.
3.6. ARK5 maintains tolerance to glucose starvation in HTLV-1-infected T-cells
Finally, we investigated the role of ARK5 on the growth of HTLV-1-infected T-cells. Knock‐
down of ARK5 expression in MT-2 (Figure 6A, upper panels) and HUT-102 (Figure 6A, lower
panels) cells did not affect growth of cells in the complete medium, which contained 2000
mg/mL glucose (Figure 6A, left panels). In contrast, knockdown of ARK5 expression reduced
the cell growth in the glucose-free medium (Figure 6A, right panels). The knockdown efficien‐
cy was analyzed by real-time RT-PCR and almost equal knockdown efficiency was detected
between with and without glucose conditions in both cell lines (Figure 6B). These results sug‐
gest that ARK5 maintains tolerance to glucose starvation in HTLV-1-infected T-cells.
Figure 5. NF-κB inhibitor suppresses ARK5 expression in an HTLV-1-infected T-cell line. (A) MT-2 cells were treated
with IκBα phosphorylation inhibitor Bay11-7082 (10 μM) or PI3K inhibitor LY249002 (20 μM) for 24 h. ARK5 expres‐
sion was analyzed by real time RT-PCR (left panel). Inhibition of phosphorylation and stabilization of IκBα protein by
treatment with Bay11-7082 and inhibition of phosphorylation of AKT by treatment with LY249002 were confirmed by
Western blotting (right panels). (B) NF-κB inhibitor reduces DNA-binding of NF-κB protein to ARK5 gene promoter in
an HTLV-1-infected T-cell line. MT-2 cells were treated with increasing amounts of Bay 11-7082 (0, 1, 5 or 10 μM) for
the indicated time periods. DNA-binding of NF-κB proteins to ARK5 promoter was analyzed by EMSA using the ARK5
κB A (top) andARK5 κB B(bottom) oligonucleotide probes containing the NF-κB-binding sites from ARK5 gene.
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4. Discussion
Some tumor cells have a strong tolerance to nutrient starvation; tolerance to glucose starva‐
tion can be induced by hypoxia. AKT and AMPK appear to be involved closely in the mech‐
anism of tolerance [47-49]. ATL cells often invade the lung, liver, bone, intestine and nerves.
Invading leukemia cells might be under nutrient-starvation condition. Therefore, we investi‐
gated the roles of ARK5, which is a member of the AMPK family and downstream target of
AKT in leukemogenesis by HTLV-1. The results of this study showed high expression of
ARK5 and c-Maf in HTLV-1-infected T-cells and that such expression was induced by
HTLV-1 Tax (Figure 1 and 2). The promoter region of ARK5 gene has MARE site where c-
Maf binds and activates transcription [24]. Unexpectedly, c-Maf induced neither transcrip‐
tional activity of ARK5 promoter nor expression of ARK5 mRNA in T lymphocytes (Figure
3), suggesting that transactivation of ARK5 promoter through MARE by c-Maf is cell type-
dependent. What is the important transcription factor that inducesARK5 gene expression?
We analyzed the nucleotide database and found two putative NF-κB sites on the promoter
of ARK5 gene. Tax induced the transcriptional activity of ARK5 gene promoter through acti‐
vation of NF-κB signaling pathway (Figure 4). This is the first report showing the involve‐
ment of NF-κB in the transcription of ARK5 gene.
NF-κB signaling pathway is not only activated by Tax but also constitutively activated in
primary ATL cells which express little amount of Tax [16]. Therefore, NF-κB inhibitors are
promising therapeutic agents for ATL. At present, several trials are being conducted using
the Bay11-7082 [50] and the proteasome inhibitor PS-341 [51] for treatment of ATL. Recently,
a new NF-κB inhibitor, dehydroxy-methyle poxy-quinomicin, has been found to inhibit NF-
κB signaling pathway induced by Tax as well as the constitutive NF-κB activation in pri‐
mary ATL cells, without affecting normal peripheral blood mononuclear cells [52, 53]. In the
present study, we demonstrated that Bay11-7082 reduced ARK5 expression in an HTLV-1-
infected T-cell line (Figure 5), suggesting that NF-κB inhibitors may modulate ATL cells in‐
vasion into multiple organs.
Another important finding in this study is that ARK5 is necessary for the growth of
HTLV-1-infected T-cells during glucose starvation (Figure 6). Previously, we and others
have demonstrated activation of PI3K/AKT signaling in HTLV-1-infected T-cells and Tax-ex‐
pressing cells [54]. These findings are important because PI3K/AKT signaling is required for
malignant growth of HTLV-1-infected T-cells [55, 56]. However, there are numerous other
downstream targets of PI3K/AKT [57]. ARK5, one of the downstream targets of PI3K/AKT
signaling, contains the consensus sequence of the AKT phosphorylation at amino acids
595-600, and is directly activated by AKT [21, 23]. We propose that Tax has dual roles as an
accelerator to induce glucose tolerance in HTLV-1-infected T-cells (Figure 7); 1) induction of
ARK5 expression through NF-κB activation (present study), and 2) activation of PI3K/AKT
signaling pathway [55, 56].
The molecular mechanisms of induction of tolerance to glucose starvation by ARK5 in
HTLV-1-infected T-cells are not elucidated in this study. Previous studies showed that dur‐
ing glucose starvation, survival of human hepatoma HepG2 cells is induced by ARK5 and
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activation of ARK5 by AKT is necessary for this effect [22, 23]. Glucose tolerance induced by
ARK5 in HTLV-1-infected T-cells may also require phosphorylation and activation of ARK5
by AKT. However, we did not analyze the phosphorylation levels or activity of ARK5 in
HTLV-1-infected T-cell lines, because a suitable antibody that can recognize phosphorylated
ARK5 is not available commercially at present time. ARK5 also negatively regulates death
receptors, such as Fas ligand-, TNF-and TRAIL-mediated cell death [22, 58]. When Fas is ac‐
tivated by the ligation of Fas ligand, intracellular interaction of the Fas-death domain, FADD
and caspase-8 (death-inducing signaling complex (DISC) recruitment) is initiated for the ac‐
tivation of executioner caspase [59], and c-FLIP is the inhibitor of DISC recruitment. ARK5
directly inactivates caspase-6 through the phosphorylation at Ser257, resulting in c-FLIP pres‐
ervation, which in turn suppresses DISC formation [58]. Although cell death during glucose
starvation is independent of death receptor, DISC recruitment is needed to induce cell death
[22]. In this way, ARK5 may prevent cell death during glucose starvation.
Figure 6. ARK5 maintains tolerance to glucose starvation in HTLV-1-infected T-cell lines. (A) MT-2 cells were transfect‐
ed with either ARK5 siRNA (solid bars) or control siRNA (open bars) at final concentration of 100 nM. Cells were incu‐
bated in glucose containing (+; 2000 mg/L) or glucose-free (-) RPMI for the indicated time points. The effect of siRNA
on cell growth was examined by counting the number of viable cells in triplicate by trypanblue dye-exclusion method.
Data are mean ± SD of triplicate experiments (*p<0.05). (B) Efficacy of knockdown by ARK5 siRNA in either glucose-
containing or glucose-free medium was determined by detecting the expression of ARK5 mRNA by real-time RT-PCR.
Results are shown as fold change of mRNA expression relative to that in control siRNA transfected cells. Real-time RT-
PCR data were obtained using the ΔΔCt method, with normalization to the reference GAPDH mRNA. Data are mean ±
SD of triplicate experiments.
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Figure 7. Schematic representation of the effects of Tax on ARK5 expression and AKT activation. Tax induces ARK5
expression by activating NF-κB signaling pathway. AKT is phosphorylated and activated through Tax-induced activa‐
tion of PI3K. c-Maf is also induced by Tax, but it does not induce ARK5 expression. Activated AKT could phosphorylate
and activate ARK5, resulting in tolerance to glucose starvation.
The results showed that c-Maf is highly expressed in HTLV-1-infected T-cells and induced
by Tax in T cells (Figure 1 and 2). A previous study showed that c-Maf is expressed in ATL
cells in lymph nodes of patients [27]. c-Maf transgenic mice develop T-cell lymphoma and
ARK5 is upregulated in c-Maf transgenic thymocytes and T lymphoma cells [27]. In contrast,
we found that c-Maf did not activate ARK5 promoter transcription in T-cells. However, c-
Maf encodes a Th2-specific transcription factor that activates the expression of IL-4 and
IL-10 in T cells [60]. In this regard, a subpopulation of ATL cells produces Th2-associated
cytokines [61]. Taken together, it is of interest to identify other downstream target genes re‐
sponsible for the actions of c-Maf that might contribute to malignant transformation of T
cells. For example, some of the target genes of c-Maf, such as those that encode cyclin D2
and integrin β7, have deregulated expression in c-Maf transgenic mice [27]. It might be in‐
teresting to investigate the role of c-Maf in the regulation of expression of these genes in
ATL cells.
5. Conclusion
We demonstrated overexpression of ARK5 in HTLV-1-infected T-cells and that Tax induced
ARK5 expression by activating the NF-κB signaling pathway. The results also indicated that
ARK5 enhanced the growth of HTLV-1-infected T-cells during glucose starvation. The
PI3K/AKT pathway, because of its central roles in cell survival, is a target for induction of
cell death in HTLV-1-infected T-cells. Thus, ARK5, a downstream target of this pathway, be‐
comes an attractive target in treatment of ATL with invasion of leukemia cells into multiple
tissues.
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